About News How to target opioid funding to states that need it most May 17, 2021 Christopher J. Ruhm How to target opioid funding to states that need it most Photo courtesy of The Hill. (iStock)More than 840,000 Americans died from drug deaths in the past two decades, and 60 percent of those deaths involved opioids. One recent study estimated the societal costs of opioid use disorder and fatal opioid overdoses at over $1 trillion in 2017 alone. This national crisis has spurred state and local governments to foster opioid misuse prevention, treatment, education and monitoring. The federal government has responded to the situation in a range of ways, including by offering financial support to states for their efforts. However, until recently, it was not well understood how well these federal funds were targeting the geographic areas with the greatest need. A study that I conducted with Bradley Katcher aimed to close this knowledge gap. In it, we compared the amount of federal grant money awarded to each state in 2017 and 2018 to the severity of the states’ opioid problems. To do this, we constructed a database of opioid-related grants from the federal government that were geographically targeted. Using our preferred measure of opioid severity — which combined the prevalence of opioid-involved drug deaths with the level of opioid misuse — we determined that around one-sixth of the funds meeting our inclusion criteria, or approximately $1.5 billion, would have needed to be reallocated in order to distribute funding in a way that was actually equitable. Read full article in The Hill Christopher J. Ruhm Christopher J. Ruhm is a professor of public policy and economics at the Frank Batten School of Leadership and Public Policy. Ruhm’s recent research has focused on the role of government policies in helping parents with young children balance the competing needs of work and family life, and on examining how various aspects of health are produced – including the growth and sources of drug poisoning deaths in the United States, the rise in obesity and the relationship between macroeconomic conditions and health. Read full bio Related Content Christopher J. Ruhm Estimated Prevalence of and Factors Associated With Clinically Significant Anxiety and Depression Among US Adults During the First Year of the COVID-19 Pandemic Research How much did clinically significant anxiety and depression increase among US adults during the first year of the COVID-19 pandemic? In this survey study of more than 1.4 million respondents in the US Behavioral Risk Factor Surveillance System survey, responses to a screening question calibrated to a 4-item Patient Health Questionnaire score of 6 or greater suggested that aggregate prevalence of clinically significant anxiety and depression increased only modestly overall among US adults in 2020 compared with 2017 to 2019. The Opioid Crisis, Health, Healthcare, and Crime: A Review Of Quasi-Experimental Economic Studies Research This study reviews quasi-experimental studies that examine the relationship between opioids and health and healthcare, and crime outcomes in the U.S. Batten Showcase 2022: Family and Medical Leave Policies in the US: Where We Are and How We Got Here ft. Chris Ruhm News In this lecture, professor of public policy and economics at the Frank Batten School of Leadership and Public Policy, Chris Ruhm, discusses family medical leave policy in the United States. Ruhm looks at where we are now, how we got here and how to move forward. We May Not Have Been as Anxious, Depressed in Pandemic's First Year as Once Thought News Findings from the Batten School's Christopher Ruhm and colleagues at Harvard question the accuracy of the CDC’s Household Pulse survey on mental health. Stay Up To Date with the Latest Batten News and Events Subscribe
Christopher J. Ruhm Christopher J. Ruhm is a professor of public policy and economics at the Frank Batten School of Leadership and Public Policy. Ruhm’s recent research has focused on the role of government policies in helping parents with young children balance the competing needs of work and family life, and on examining how various aspects of health are produced – including the growth and sources of drug poisoning deaths in the United States, the rise in obesity and the relationship between macroeconomic conditions and health. Read full bio
Estimated Prevalence of and Factors Associated With Clinically Significant Anxiety and Depression Among US Adults During the First Year of the COVID-19 Pandemic Research How much did clinically significant anxiety and depression increase among US adults during the first year of the COVID-19 pandemic? In this survey study of more than 1.4 million respondents in the US Behavioral Risk Factor Surveillance System survey, responses to a screening question calibrated to a 4-item Patient Health Questionnaire score of 6 or greater suggested that aggregate prevalence of clinically significant anxiety and depression increased only modestly overall among US adults in 2020 compared with 2017 to 2019.
The Opioid Crisis, Health, Healthcare, and Crime: A Review Of Quasi-Experimental Economic Studies Research This study reviews quasi-experimental studies that examine the relationship between opioids and health and healthcare, and crime outcomes in the U.S.
Batten Showcase 2022: Family and Medical Leave Policies in the US: Where We Are and How We Got Here ft. Chris Ruhm News In this lecture, professor of public policy and economics at the Frank Batten School of Leadership and Public Policy, Chris Ruhm, discusses family medical leave policy in the United States. Ruhm looks at where we are now, how we got here and how to move forward.
We May Not Have Been as Anxious, Depressed in Pandemic's First Year as Once Thought News Findings from the Batten School's Christopher Ruhm and colleagues at Harvard question the accuracy of the CDC’s Household Pulse survey on mental health.